(1 - 7 from 11
)
Atox Bio to advance AB103 Phase 2 study with $3.25M financing
www.news-medical.net
"We are very pleased with this financing round," stated Dan Teleman, CEO of Atox Bio "This achievement reflects our investors' confidence in our novel approach to
sorted by relevance / date